Badri Dasu Biography and Net Worth

Chief Engineering Officer of Talphera

Mr. Dasu has served as chief engineering officer since September 2007.

Prior to joining AceclRx, Mr. Dasu served as vice president of medical device engineering at Anesiva, Inc.,,and as vice president for manufacturing and device development at AlgoRx Pharmaceuticals, Inc., an emerging pain management company that merged with Corgentech, Inc. in December 2005.

Earlier in his career, Mr. Dasu served as vice president of manufacturing and process development at PowderJect Pharmaceuticals, which was acquired by Chiron Corporation in 2003. Mr. Dasu has also held positions in process development at Metrika Inc., which was acquired by Bayer HealthCare, LLC in 2006, and at Cygnus, Inc., a drug delivery and specialty pharmaceuticals company. Mr. Dasu holds a Bachelor of Engineering in chemical engineering from the University of Mangalore, India and a Master of Science in chemical engineering from the University of Tulsa.

What is Badri N. Dasu's net worth?: The estimated net worth of Badri N. Dasu is at least $88.81 thousand as of February 12th, 2026. Mr. Dasu owns 76,230 shares of Talphera stock worth more than $88,808 as of September 23rd. This net worth approximation does not reflect any other investments that Mr. Dasu may own. Learn More about Badri N. Dasu's net worth.
How do I contact Badri N. Dasu?: The corporate mailing address for Mr. Dasu and other Talphera executives is 1850 Gateway Drive, Suite 175, San Mateo, CA, 94404. Talphera can also be reached via phone at 650-216-3500 and via email at [email protected]. Learn More on Badri N. Dasu's contact information.
Has Badri N. Dasu been buying or selling shares of Talphera?: Badri N. Dasu has not been actively trading shares of Talphera in the last ninety days. Most recently, on Thursday, February 12th, Badri N. Dasu bought 35,000 shares of Talphera stock. The stock was acquired at an average cost of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider now directly owns 76,230 shares of the company's stock, valued at $61,746.30. Learn More on Badri N. Dasu's trading history.
Are insiders buying or selling shares of Talphera?: In the last year, Talphera insiders bought shares 5 times. They purchased a total of 433,674 shares worth more than $304,347.74. The most recent insider tranaction occured on March, 13th when CEO Vincent J Angotti bought 213,310 shares worth more than $125,852.90. Insiders at Talphera own 3.5% of the company. Learn More about insider trades at Talphera.
Information on this page was last updated on 3/13/2026.

Badri N. Dasu Insider Trading History at Talphera

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	35,000	$0.81	$28,350.00	76,230

Badri N. Dasu Buying and Selling Activity at Talphera

Talphera Company Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Today's Range

Now: $1.17

$1.15

$1.18

50 Day Range

MA: $1.27

$1.16

$1.47

2 Week Range

Now: $1.17

$0.69

$1.57

Volume

70,738 shs

Average Volume

241,863 shs

Market Capitalization

$60.48 million

P/E Ratio

N/A

Dividend Yield